WuXi AppTec Co., Ltd. Class A 603259

Investing.com -- Bernstein has identified several China-based biopharmaceutical companies positioned to benefit from evolving drug development capabilities, with a focus on integrated platforms and service providers that support AI-enabled research and development workflows.

Stricter quality rules, complex biologics and outsourcing are driving demand for impurity isolation, synthesis and analytics, creating opportunities for specialized labs and CROs.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Impurity Synthesis and Isolation Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical impurity synthesis and isolation services market was valued at US$1.3 billion in 2024 and is projected to

Opportunities center on AI-enabled decentralized trials, therapeutic specialization, global patient recruitment, regulatory support, real-world evidence and integrated partnerships.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Contract Research Organization Services Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Contract Research Organization Services Market research report provides strategic analysis of a sector projected to reach USD 87.43 billion in

Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Services was estimated at US$10.8 Billion in 2025 and is projected to reach US$26.3 Billion by 2032, growing at a CAGR of 13.6% from 2025 to

Demand for outsourced pharmacokinetics services is rising, driven by AI, advanced bioanalysis, personalized medicine, biologics and complex global trials.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Pharmacokinetics Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pharmacokinetics Services was estimated at US$853.5 Million in 2025 and is projected to reach US$1.4 Billion by 2032, growing at a CAGR of 7.8% from 2025 to 2032. Thi

Stricter safety rules, drug innovation and CRO outsourcing drive demand, while imaging, CRISPR and data analytics improve testing and reduce animal use.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "In Vivo Toxicology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for In Vivo Toxicology was estimated at US$4.5 Billion in 2025 and is projected to reach US$6.0 Billion by 2032, growing at a CAGR of 4.3% from 2025 to 2032. This comprehensive re

Pharma companies are expanding drug discovery outsourcing to cut costs, access CRO expertise and AI tools, speed pipelines, manage regulatory complexity, and advance targeted therapies.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Outsourcing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Outsourcing was estimated at US$2.8 Billion in 2025 and is projected to reach US$4.5 Billion by 2032, growing at a CAGR

Stricter safety rules and drug innovation are boosting demand, while high-throughput screening, predictive analytics, biomarkers, and non-animal methods create new opportunities.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Toxicology Testing Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Toxicology Testing Services was estimated at US$41.6 Billion in 2025 and is projected to reach US$59.8 Billion by 2032, growing at a CAGR of

If you are looking for stocks that are well positioned to maintain their recent uptrend, Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Demand is rising for faster, accurate ADME-Tox testing, driven by complex biologics, tighter regulation, personalized medicine, and adoption of high-throughput, in vitro and in silico methods.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "ADME-Toxicology Testing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for ADME-Toxicology Testing was valued at US$10 Billion in 2024 and is projected to reach US$18.8 Billion by 2030, growing at a CAGR o

Longer-lasting activity is a defining feature of the next generation of oligonucleotide medicines, with chemical modifications, conjugation, and tissue-targeting strategies helping extend pharmacological activity from days toward months.Engineering longer-lasting oligonucleotides often requires more complex conjugate architectures, which in turn add complexity to synthesis, purification, analytical characterization, and scalable manufacturing.Long-acting design raises the development bar, requir

Beyond-liver delivery is becoming the next major frontier for oligonucleotide medicines, with growing efforts to reach muscle, the central nervous system, lung, immune cells and tumors.No single delivery technology is likely to work across all tissues. Antibody conjugates, peptides, lipid conjugates and targeted nanoparticles are being tailored to specific receptors, cell types and biological barriers.Delivery strategy shapes the entire downstream program, influencing biodistribution, dose and d

WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend. Building on its inaugural interim dividend of RMB 1.03 billion in 2025, the Company has further increased its 2026 interim dividend payout to RMB 1.51 billion. While accelerating the expansion of global capacity and capabilities, the Company remains committed to returning value

Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

A federal judge on Friday barred the U.S. Defense Department from including Chinese biotechnology company WuXi AppTec Co ‌on a list of companies believed to support Beijing's military, saying the government lacked ‌evidence to justify the decision. U.S. District Judge James Boasberg issued an order to block enforcement of the designation of ​WuXi in June after the company filed suit. "A scarlet letter sends a clear message: keep away," Boasberg wrote, noting that since then, WuXi’s customers and suppliers have canceled contracts, terminated longstanding relationships, and moved their busines

WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first half ending June 30, 2026 ("Reporting Period"). The Company raised its full-year guidance, citing strong performance across revenue, profit, and cash flow driven by the greater success of multiple customers' products and its unique integrated CRDMO platform.

WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announced it has been named in the FTSE4Good Index Series for the fourth consecutive year, reflecting the Company's sustained commitment to sustainability.

A Chinese biotechnology company sued the U.S. government on Thursday over being placed on a list of businesses from ‌China that the U.S. Department of Defense has linked to that country's military. WuXi AppTec filed ‌its complaint in the Washington, D.C., federal court, calling its inclusion on the list arbitrary, capricious, unsupported by the facts and "the product ​of political pressure." The lawsuit seeks WuXi's removal from the list.

A spokesperson for the Chinese company said “we will take immediate action” following the military designation.